Rubicon Genomics, Inc.

Pharmacogenomics

Rubicon Genomics, Inc., 4370 Varsity Drive, Suite G, Ann Arbor, MI 48108, USA.

Published: July 2002

Rubicon Genomics, Inc. is a leader in development and application of effective methods to analyze human DNA for genome-wide genotyping and haplotyping. The company is developing its proprietary OmniPlex technology as an integrated platform for archiving, amplifying and analyzing patient DNA for drug target discovery, pharmacogenomics and diagnostics. Single-site, multiple-site or whole genome amplification can be done using small samples of DNA that have been archived as OmniPlex DNA. Rubicon technology will make genome-wide SNP scoring faster, more accurate, more robust and less expensive. Rubicon will partner with pharmaceutical and diagnostic companies, as well as the makers of instruments and reagents to bring OmniPlex technology to the widest market - increasing the pipeline of more effective and safer drugs and ushering in the practice of gene-based medicine.

Download full-text PDF

Source
http://dx.doi.org/10.1517/14622416.3.4.557DOI Listing

Publication Analysis

Top Keywords

rubicon genomics
8
omniplex technology
8
rubicon
4
genomics rubicon
4
genomics leader
4
leader development
4
development application
4
application effective
4
effective methods
4
methods analyze
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!